Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Hussain

Showing results (61-70 of 213) with videos related to

Pageof 22
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 23, 2023
Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized TreatmentAnis A Hamid, Nicolas Sayegh, Bertrand Tombal, et al.
Cancer Research|April 19, 2007
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancerSanjeev Banerjee, Maha Hussain, Zhiwei Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2022
Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspectiveThomas J Herzog, Ignace Vergote, Leonard G Gomella, et al.
Clinical Prostate Cancer|March 30, 2004
Ten-year survival in patients with metastatic prostate cancerCatherine M Tangen, James R Faulkner, E David Crawford, et al.
Clinical Genitourinary Cancer|February 15, 2008
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study designDeborah A Bradley, Rodney Dunn, David Nanus, et al.
Advances in Radiation Oncology|July 21, 2021
Trimodality Treatment for Muscle-Invasive Bladder Cancer: An Institutional ExperiencePraneet Polineni, Laura Ashack, John Kalapurakal, et al.
The Journal of Urology|March 27, 2007
Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancerAlon Z Weizer, Daya Joshi, Stephanie Daignault, et al.
Investigational New Drugs|March 4, 2005
Phase II trial of fenretinide in advanced renal carcinomaUlka Vaishampayan, Lance K Heilbrun, Ralph E Parchment, et al.
The Lancet. Oncology|February 17, 2019
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trialBertrand Tombal, Fred Saad, David Penson, et al.
Urology|April 3, 2003
Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancerMaha Hussain, David C Smith, Basil F El-Rayes, et al.
Pageof 22

Showing results (61-70 of 213) with videos related to

Sort By:
Pageof 22
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 23, 2023
Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized TreatmentAnis A Hamid, Nicolas Sayegh, Bertrand Tombal, et al.
Cancer Research|April 19, 2007
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancerSanjeev Banerjee, Maha Hussain, Zhiwei Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2022
Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspectiveThomas J Herzog, Ignace Vergote, Leonard G Gomella, et al.
Clinical Prostate Cancer|March 30, 2004
Ten-year survival in patients with metastatic prostate cancerCatherine M Tangen, James R Faulkner, E David Crawford, et al.
Clinical Genitourinary Cancer|February 15, 2008
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study designDeborah A Bradley, Rodney Dunn, David Nanus, et al.
Advances in Radiation Oncology|July 21, 2021
Trimodality Treatment for Muscle-Invasive Bladder Cancer: An Institutional ExperiencePraneet Polineni, Laura Ashack, John Kalapurakal, et al.
The Journal of Urology|March 27, 2007
Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancerAlon Z Weizer, Daya Joshi, Stephanie Daignault, et al.
Investigational New Drugs|March 4, 2005
Phase II trial of fenretinide in advanced renal carcinomaUlka Vaishampayan, Lance K Heilbrun, Ralph E Parchment, et al.
The Lancet. Oncology|February 17, 2019
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trialBertrand Tombal, Fred Saad, David Penson, et al.
Urology|April 3, 2003
Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancerMaha Hussain, David C Smith, Basil F El-Rayes, et al.
Pageof 22